Global Osteoarthritis Gene Therapy Market Analysis and Forecast 2025 – 2035

The Global Osteoarthritis Gene Therapy Market Size was worth around USD 8.09 Billion in 2024 and is predicted to grow to around USD 18.50 Billion by 2035 with a compound annual growth rate (CAGR) of 7.81% from 2025 and 2035. The market for osteoarthritis gene therapy has a number of opportunities to grow due to the surging emphasis on stem cell therapy. Further, advancements like CRISPR-Cas9 gene editing, nanotechnology-driven, non-viral delivery systems, and personalized medicine approaches are enhancing precision, safety, and durability.

Market Overview

The global osteoarthritis gene therapy industry is an emerging, high-growth sector focused on disease-modifying, long-term treatments rather than just pain relief, by the use of gene editing (like CRISPR-Cas9) and viral vectors for targeting cartilage degeneration and inflammation, with several candidates (like GNSC-001) in clinical trials showing promising results. Unlike pharmacological treatments, which are administered locally or systemically as a series of interventions, gene therapy aims to establish a sustained therapeutic effect after a single, local injection.

Innovation and market expansion are anticipated as a result of major players' growing R&D expenditures and expanding partnerships. For instance, in December 2025, Pacira Biosciences, Inc., the industry leader in the delivery of innovative, non-opioid pain therapies, announced it has joined the PROBE (Patient Relevant Osteoarthritis endpoints using Big data Evaluation) Consortium, a pioneering initiative to revolutionize osteoarthritis (OA) research and improve patient care and outcomes on a global scale.